MAM
INO icon

Martingale Asset Management’s Inovio Pharmaceuticals INO Stock Holding History

Martingale Asset Management’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,338
Closed -$81K – 837
2021
Q4 		$81K Sell
1,338
-2,042
-60% -$164K ﹤0.01% 810
2021
Q3 		$291K Buy
3,380
+933
+38% +$93.6K ﹤0.01% 758
2021
Q2 		$273K Buy
+2,447
New +$235K ﹤0.01% 737

Other funds holding INO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Martingale Asset Management's INO Position: Q1 2022 in Review

Martingale Asset Management sold out of Inovio Pharmaceuticals (INO) in Q1 2022, closing a stake of 1,338 shares — an estimated $81K sold.

Martingale Asset Management first reported a position in INO in Q2 2021 and held it in 3 quarters. The position peaked at $291K in Q3 2021. 198 funds tracked by Wall St. Rank hold INO as of Q1 2022.

  • Martingale Asset Management reported no remaining Inovio Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Martingale Asset Management sold 1,338 Inovio Pharmaceuticals shares in Q1 2022, an estimated $81K.
  • Martingale Asset Management first reported a position in Inovio Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • Martingale Asset Management's Inovio Pharmaceuticals position peaked at $291K in Q3 2021.
  • 198 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2022.

Based on Martingale Asset Management's 13F filing for Q1 2022, filed 12 May 2022.